Screens, maps & networks: From genome sequences to personalized medicine

Current Opinion in Genetics and Development

Volumn 22, Issue 1, 2012, Pages 36-44

  Sandmann, Thomas ^a   Boutros, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GUANOSINE TRIPHOSPHATASE; K RAS PROTEIN; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR PAX8; VEMURAFENIB;

CANCER CELL; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GENETICS; DRUG EFFICACY; GENE INTERACTION; GENE LOCUS; GENE MAPPING; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; MELANOMA; ONCOGENE C ERB; ONCOGENE C H RAS; ONCOGENE K RAS; ONCOGENE N RAS; OVARY CANCER; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; RNA SPLICING; SIGNAL TRANSDUCTION; TUMOR GENE;

ANIMALS; BASE SEQUENCE; GENOME; HUMANS; INDIVIDUALIZED MEDICINE; PHENOTYPE; RNA INTERFERENCE;

EID: 84858440807     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2012.02.001     Document Type: Review

References (54)

1. Bell D., Berchuck A., Birrer M., Chien J., Cramer D., Dao F., Dhir R., DiSaia P., Gabra H., Glenn P., et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
2. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., Sboner A., Esgueva R., Pflueger D., Sougnez C., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
3. McLendon R., Friedman A., Bigner D., Van Meir E.G., Brat D.J., Mastrogianakis G.M., Olson J.J., Mikkelsen T., Lehman N., Aldape K., et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
4. Shah S.P., Morin R.D., Khattra J., Prentice L., Pugh T., Burleigh A., Delaney A., Gelmon K., Guliany R., Senz J., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
5. Bainbridge M.N., Wiszniewski W., Murdock D.R., Friedman J., Gonzaga-Jauregui C., Newsham I., Reid J.G., Fink J.K., Morgan M.B., Gingras M.-C., et al. Whole-genome sequencing for optimized patient management. Science Translational Medicine 2011, 3:87re83.
6. Jones S.J., Laskin J., Li Y.Y., Griffith O.L., An J., Bilenky M., Butterfield Y.S., Cezard T., Chuah E., Corbett R., et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biology 2010, 11:R82.
7. Ng S.B., Buckingham K.J., Lee C., Bigham A.W., Tabor H.K., Dent K.M., Huff C.D., Shannon P.T., Jabs E.W., Nickerson D.A., et al. Exome sequencing identifies the cause of a mendelian disorder. Nature Genetics 2010, 42:30-35.
8. Welch J.S., Westervelt P., Ding L., Larson D.E., Klco J.M., Kulkarni S., Wallis J., Chen K., Payton J.E., Fulton R.S., et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA: The Journal of the American Medical Association 2011, 305:1577-1584.
9. Worthey E.A., Mayer A.N., Syverson G.D., Helbling D., Bonacci B.B., Decker B., Serpe J.M., Dasu T., Tschannen M.R., Veith R.L., et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genetics in Medicine: Official Journal of the American College of Medical Genetics 2011, 13:255-262.
10. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., Rahman N., Stratton M.R. A census of human cancer genes. Nature Reviews. Cancer 2004, 4:177-183.
11. Shoemaker R.H. The NCI60 human tumour cell line anticancer drug screen. Nature Reviews. Cancer 2006, 6:813-823.
12. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
13. Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., et al. Signatures of mutation and selection in the cancer genome. Nature 2010, 463:893-898.
14. Cheung H.W., Cowley G.S., Weir B.A., Boehm J.S., Rusin S., Scott J.A., East A., Ali L.D., Lizotte P.H., Wong T.C., et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:12372-12377.
15. Weinstein I.B. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science (New York, NY) 2002, 297:63-64.
16. Brough R., Frankum J.R., Sims D., Mackay A., Mendes-Pereira A.M., Bajrami I., Costa-Cabral S., Rafiq R., Ahmad A.S., Cerone M.A., et al. Functional viability profiles of breast cancer. Cancer Discovery 2011, 1:260-273.
17. Fisk H.A., Mattison C.P., Winey M. Human Mps1 protein kinase is required for centrosome duplication and normal mitotic progression. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:14875-14880.
18. Bos J.L. ras oncogenes in human cancer: a review. Cancer Research 1989, 49:4682-4689.
19. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
20. Karnoub A.E., Weinberg R.A. Ras oncogenes: split personalities. Nature Reviews. Molecular Cell Biology 2008, 9:517-531.
21. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
22. Nijman S.M.B. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Letters 2011, 585:1-6.
23. Barbie D.A., Tamayo P., Boehm J.S., Kim S.Y., Moody S.E., Dunn I.F., Schinzel A.C., Sandy P., Meylan E., Scholl C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112.
24. Scholl C., Fröhling S., Dunn I.F., Schinzel A.C., Barbie D.A., Kim S.Y., Silver S.J., Tamayo P., Wadlow R.C., Ramaswamy S., et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137:821-834.
25. Babij C., Zhang Y., Kurzeja R.J., Munzli A., Shehabeldin A., Fernando M., Quon K., Kassner P.D., Ruefli-Brasse A.A., Watson V.J., et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Research 2011, 71:5818-5826.
26. Luo J., Emanuele M.J., Li D., Creighton C.J., Schlabach M.R., Westbrook T.F., Wong K.-K., Elledge S.J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
27. Torrance C.J., Agrawal V., Vogelstein B., Kinzler K.W. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nature Biotechnology 2001, 19:940-945.
28. Solimini N.L., Luo J., Elledge S.J. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 2007, 130:986-988.
29. Evers B., Schut E., van der Burg E., Braumuller T.M., Egan D.A., Holstege H., Edser P., Adams D.J., Wade-Martins R., Bouwman P., et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16:99-108.
30. Krastev D.B., Slabicki M., Paszkowski-Rogacz M., Hubner N.C., Junqueira M., Shevchenko A., Mann M., Neugebauer K.M., Buchholz F. A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly. Nature Cell Biology 2011, 13:809-818.
31. Wang Y., Ngo V.N., Marani M., Yang Y., Wright G., Staudt L.M., Downward J. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 2010, 29:4658-4670.
32. Forsburg S.L. The art and design of genetic screens: yeast. Nature Reviews. Genetics 2001, 2:659-668.
33. Lehner B., Tischler J., Fraser A.G. RNAi screens in Caenorhabditis elegans in a 96-well liquid format and their application to the systematic identification of genetic interactions. Nature Protocols 2006, 1:1617-1620.
34. Lehner B., Crombie C., Tischler J., Fortunato A., Fraser A.G. Systematic mapping of genetic interactions in Caenorhabditis elegans identifies common modifiers of diverse signaling pathways. Nature Genetics 2006, 38:896-903.
35. St Johnston D. The art and design of genetic screens: Drosophila melanogaster. Nature Reviews. Genetics 2002, 3:176-188.
36. Collins S.R., Miller K.M., Maas N.L., Roguev A., Fillingham J., Chu C.S., Schuldiner M., Gebbia M., Recht J., Shales M., et al. Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map. Nature 2007, 446:806-810.
37. Costanzo M., Baryshnikova A., Bellay J., Kim Y., Spear E.D., Sevier C.S., Ding H., Koh J.L.Y., Toufighi K., Mostafavi S., et al. The genetic landscape of a cell. Science (New York, NY) 2010, 327:425-431.
38. Magtanong L., Ho C.H., Barker S.L., Jiao W., Baryshnikova A., Bahr S., Smith A.M., Heisler L.E., Choy J.S., Kuzmin E., et al. Dosage suppression genetic interaction networks enhance functional wiring diagrams of the cell. Nature Biotechnology 2011, 29:505-511.
39. Beltrao P., Cagney G., Krogan N.J. Quantitative genetic interactions reveal biological modularity. Cell 2010, 141:739-745.
40. Tong A.H., Lesage G., Bader G.D., Ding H., Xu H., Xin X., Young J., Berriz G.F., Brost R.L., Chang M., et al. Global mapping of the yeast genetic interaction network. Science 2004, 303:808-813.
41. Zhao R., Davey M., Hsu Y.C., Kaplanek P., Tong A., Parsons A.B., Krogan N., Cagney G., Mai D., Greenblatt J., et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 2005, 120:715-727.
42. Roguev A., Bandyopadhyay S., Zofall M., Zhang K., Fischer T., Collins S.R., Qu H., Shales M., Park H.O., Hayles J., et al. Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast. Science 2008, 322:405-410.
43. Fiedler D., Braberg H., Mehta M., Chechik G., Cagney G., Mukherjee P., Silva A.C., Shales M., Collins S.R., van Wageningen S., et al. Functional organization of the S. cerevisiae phosphorylation network. Cell 2009, 136:952-963.
44. Bandyopadhyay S., Mehta M., Kuo D., Sung M.-K., Chuang R., Jaehnig E.J., Bodenmiller B., Licon K., Copeland W., Shales M., et al. Rewiring of genetic networks in response to DNA damage. Science (New York, NY) 2010, 330:1385-1389.
45. Horn T., Sandmann T., Fischer B., Axelsson E., Huber W., Boutros M. Mapping of signaling networks through synthetic genetic interaction analysis by RNAi. Nature Methods 2011, 8:341-346.
46. Norton B., Pearson E.S. A note on the background to, and refereeing of, R.A. Fisher's 1918 paper 'On the correlation between relatives on the supposition of Mendelian inheritance'. Notes and Records of the Royal Society of London 1976, 31:151-162.
47. Muellner M.K., Uras I.Z., Gapp B.V., Kerzendorfer C., Smida M., Lechtermann H., Craig-Mueller N., Colinge J., Duernberger G., Nijman S.M.B. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nature Chemical Biology 2011, 7:787-793.
48. Sims D., Mendes-Pereira A.M., Frankum J., Burgess D., Cerone M.A., Lombardelli C., Mitsopoulos C., Hakas J., Murugaesu N., Isacke C.M., et al. High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing. Genome Biology 2011, 12:R104.
49. Barabási A.-L., Gulbahce N., Loscalzo J. Network medicine: a network-based approach to human disease. Nature Reviews. Genetics 2011, 12:56-68.
50. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
51. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England Journal of Medicine 2011, 364:2507-2516.
52. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. The New England Journal of Medicine 2010, 363:809-819.
53. Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., Emery C.M., Stransky N., Cogdill A.P., Barretina J., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
54. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., Chen Z., Lee M.-K., Attar N., Sazegar H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.